Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by Pro Top & Mediking Company Limited.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Pro Top & Mediking Company Limited
Information provided by:
Pro Top & Mediking Company Limited
ClinicalTrials.gov Identifier:
NCT00687791
First received: May 28, 2008
Last updated: June 17, 2008
Last verified: June 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to determine the safety and effectiveness of the OculusGen™ (ologen) Biodegradable Collagen Matrix Implant in hacotrabeculectomy surgery. The primary endpoint is to prove the effectiveness via the reduction of IOP, and the secondary endpoint is to prove the safety via the incidence of complications and adverse events.
| Condition | Intervention | Phase |
|---|---|---|
|
Cataract Glaucoma |
Device: ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study |
Resource links provided by NLM:
Further study details as provided by Pro Top & Mediking Company Limited:
Primary Outcome Measures:
- The primary endpoint is to prove the effectiveness via the reduction of IOP. [ Time Frame: 180 days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- the secondary endpoint is to prove the safety via the reduction of complications. [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 20 |
| Study Start Date: | December 2007 |
| Estimated Study Completion Date: | December 2008 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
20 enrolled patients will be chosen according to the enrollment acceptance criteria. The evidence for the determination of enrolled patients shall be recorded, reviewed and approved. 2> Phacotrabeculectomy is performed.3> After completing phacotrabeculectomy, implant/place ologen™ Collagen Matrix on top of the scleral flap under the conjunctiva. For every inspection and observation, the detailed description and/or inspection data shall be recorded. If any unwanted adverse event is observed during inspection and observation, it shall be recorded and be reported to the investigation conductor.
|
Device: ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
Other Name: OculusGen (ologen™)
|
Detailed Description:
Ologen™ Collagen Matrix is indicated for creating a mature bleb structure to facilitate aqueous outflow for the reduction of elevated intraocular pressure in patients with glaucoma, following traditional filtering surgery (trabeculectomy)
Within 60 days from the time of implantation, ologen™ Collagen Matrix is totally degraded. Postoperatively, mild inflammation may be seen and anti- inflammatory agents are prescribed
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 18 years or over.
- At least one eye diagnosed with glaucoma and receiving maximally tolerated medical therapy.
- Visually significant cataract with visual acuity of less than or equal to 6/12.
- Subject able and willing to cooperate with investigation plan.
- Subject willing to sign informed consent form.
Exclusion Criteria:
- Known allergic reaction to collagen.
- Subject is on Warfarin and discontinuation is not recommended.
- Subject with normal tension glaucoma or aphakic glaucoma.
- Subject with corneal disease.
- Participation in an investigational study during the 30 days proceeding phacotrabeculectomy.
- Ocular infection within 14 days prior to phacotrabeculectomy.
- Pregnant or breast-feeding women.
- Monocular subject.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00687791
Contacts
| Contact: Aung Tin, PhD MD | +65-62277255 | aung.tin@snec.com.sg |
Locations
| Singapore | |
| Singapore Eye Research Institute | Recruiting |
| Singapore, Singapore, 168751 | |
Sponsors and Collaborators
Pro Top & Mediking Company Limited
Investigators
| Study Chair: | Aung Tin, PhD MD | Singapore Eye Research Institute |
More Information
Additional Information:
No publications provided
| Responsible Party: | Assoc. Prof. Aung Tin, Singapore Eye Research Institute |
| ClinicalTrials.gov Identifier: | NCT00687791 History of Changes |
| Other Study ID Numbers: | Mediking 0706 |
| Study First Received: | May 28, 2008 |
| Last Updated: | June 17, 2008 |
| Health Authority: | Singapore: Ministry of Health |
Keywords provided by Pro Top & Mediking Company Limited:
|
patients with cataract and glaucoma ologen oculusgen collagen matrix Phacotrabeculectomy |
Aeon Astron trabeculectomy tissue engineering mitomycin-C |
Additional relevant MeSH terms:
|
Glaucoma Cataract Ocular Hypertension Eye Diseases Lens Diseases |
ClinicalTrials.gov processed this record on June 17, 2013